Are there any medications that combine ketamine with an SSRI or other psychiatric medication?

Ketamine Combined with SSRIs and Other Psychiatric Medications

Yes, ketamine and esketamine are routinely combined with SSRIs or SNRIs in clinical practice, and this combination is actually the FDA-approved standard for esketamine treatment. 1

FDA-Approved Combination: Esketamine + SSRI/SNRI

Esketamine (intranasal Spravato) is approved exclusively in combination with an SSRI or SNRI—it cannot be prescribed as monotherapy. 2 This represents the only formally approved medication regimen combining ketamine-class drugs with psychiatric medications.

Key Clinical Parameters:

• Indication: Treatment-resistant depression (TRD) after failure of at least 2 adequate antidepressant trials 1
• Administration: Twice-weekly intranasal esketamine plus ongoing oral SSRI/SNRI
• Monitoring requirements: 2-hour post-treatment observation in certified healthcare settings 1
• Evidence: Meta-analysis of 5 RCTs showed improved depressive symptoms and remission rates at 28 days when esketamine augmented ongoing antidepressants 1

Off-Label IV Ketamine Combinations

IV ketamine is commonly used off-label in conjunction with ongoing antidepressants, though this lacks formal FDA approval. 1 Meta-analysis of 20 RCTs demonstrated that ketamine added to ongoing antidepressant treatment showed significant improvement for up to 7 days, whereas ketamine monotherapy lost efficacy by day 7 1.

Comparative Effectiveness Data:

Recent real-world evidence (2025) comparing 55,480 matched patients found: 3

• Esketamine + SNRI: Lower all-cause mortality (5.3% vs 9.1%), fewer hospitalizations (0.1% vs 0.2%), fewer depression relapses (14.8% vs 21.2%)
• Esketamine + SSRI: Lower suicide attempts (0.3% vs 0.5%)

This suggests SNRIs may be the preferred partner for esketamine based on mortality and relapse outcomes, though SSRIs showed marginal advantage for suicide prevention. 3

Critical Drug Interactions to Avoid

Benzodiazepines - AVOID or Use Cautiously

Benzodiazepines repeatedly reduce the duration and magnitude of ketamine's antidepressant effect. 4 The FDA label warns that concomitant use may cause profound sedation, respiratory depression, coma, and death 5. If unavoidable, close monitoring of respiratory rate and pulse oximetry is mandatory 5.

Lamotrigine - Evidence is Mixed

• Animal studies suggest synergistic antidepressant effects 6, 7
• Human studies show conflicting results: 2 of 5 studies indicated lamotrigine attenuated ketamine's effects 4
• One clinical study found no enhanced antidepressant effect when combined, though only single ketamine infusion was tested 6
• Clinical verdict: Insufficient evidence to recommend routine combination; may reduce ketamine efficacy 4

Other Psychiatric Medications

Lithium: No significant interactions reported 4

Antipsychotics:

• Clozapine significantly blunts ketamine-induced effects 4
• Risperidone attenuates ketamine-induced brain perfusion changes 4
• Use caution when combining ketamine with antipsychotics

MAOIs: Case reports with tranylcypromine showed no concerning vital sign changes with S-ketamine 4

Practical Algorithm for Combination Treatment

1. First-line combination: Esketamine + SNRI (duloxetine, venlafaxine, desvenlafaxine) for TRD patients based on superior mortality and relapse outcomes 3

2. Alternative: Esketamine + SSRI if suicide risk is primary concern 3

3. Discontinue or minimize benzodiazepines at least 2 weeks before ketamine treatment to preserve antidepressant efficacy 4

4. Monitor liver function with baseline and periodic LFTs (alkaline phosphatase, GGT) for recurrent ketamine dosing 5

5. Avoid combining with: High-dose antipsychotics (especially clozapine), lamotrigine (unless compelling indication), theophylline/aminophylline (lowers seizure threshold) 5, 4

Common Pitfalls

• Assuming ketamine can be first-line treatment: Both ketamine and esketamine are reserved for patients who have failed multiple adequate antidepressant trials 1
• Continuing benzodiazepines during ketamine treatment: This significantly undermines treatment efficacy 4
• Using esketamine as monotherapy: FDA approval requires concurrent SSRI/SNRI 2
• Inadequate monitoring: Esketamine requires 2-hour post-dose observation in certified settings 1

No single-pill combination medication containing ketamine plus an SSRI/antidepressant exists—these are always administered as separate medications in a coordinated treatment plan. 1, 2